

Nilotinib in the treatment of c-KIT mutated advanced melanoma

Submission date 15/05/2009	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/07/2009	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 27/09/2024	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-nilotinib-treat-acral-mucosal-melanoma-skin-cancer-spread>

Contact information

Type(s)

Scientific

Contact name

Dr James Larkin

Contact details

The Royal Marsden Hospital NHS Foundation Trust
Fulham Road
London
United Kingdom
SW3 6JJ
+44 (0)20 7808 2132
james.larkin@rmh.nhs.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2009-012945-49

ClinicalTrials.gov (NCT)

NCT01395121

Protocol serial number

ICR-CTSU/2009/10020

Study information

Scientific Title

A phase II trial of nilotinib in the treatment of c-KIT mutated advanced acral and mucosal melanoma (NICAM)

Acronym

NICAM

Study objectives

The NICAM trial will test the hypothesis that the c-KIT tyrosine kinase inhibitor nilotinib is active in c-KIT mutant advanced acral and mucosal melanoma.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Oxfordshire C, 20/11/2009, ref: 09/H0606/103

Study design

Single-arm phase II clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Advanced acral or mucosal melanoma

Interventions

Nilotinib 400 mg twice daily (bid). Treatment will continue for as long as the patient receives clinical benefit.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Nilotinib

Primary outcome(s)

Proportion of patients progression free at 6 months

Key secondary outcome(s)

1. Response rate at 12 weeks
2. Overall survival at 6 months from treatment start

3. Toxicity of treatment at 6 months from treatment start
4. Correlation between c-KIT mutation, gene amplification, overexpression and response to treatment and survival at 6 months from treatment start
5. Changes in circulating tumour cells at 6 months from treatment start

Completion date

09/03/2017

Eligibility

Key inclusion criteria

1. Patients with c-KIT mutated histologically proven advanced mucosal or acral melanoma in which the mutation is not known to be associated with nilotinib resistance
2. Unresectable locally advanced or metastatic disease
3. The presence of one or more clinically or radiologically measurable lesions at least 10 mm in size
4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
5. Life expectancy greater than 12 weeks
6. At least 28 days since major surgery and 7 days since skin/tumour biopsy
7. The capacity to understand the patient information sheet and the ability to provide written informed consent
8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
9. Aged 18 years or greater, either sex
10. Women must be post-menopausal (no menstrual period for a minimum of 1 year) or have a negative serum pregnancy test on entry in the study (even if surgically sterilised). Men and women of childbearing potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilisation) for the duration of the study and should continue such precautions for 6 months after receiving the last study treatment.
11. Serum alanine transaminase (ALT) less than or equal to 2.5 x upper limit of normal (ULN), total serum bilirubin less than or equal to 1.5 x ULN
12. Serum creatinine less than or equal to 1.5 x ULN
13. Haemoglobin greater than or equal to 9.0 g/dL, absolute neutrophil count greater than or equal to $1.5 \times 10^9/L$, platelets greater than or equal to $100 \times 10^9/L$
14. Prothrombin time (PT) less than or equal to 1.5 x ULN

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

29

Key exclusion criteria

1. Intracranial disease, unless there has been radiological evidence of stable intracranial disease greater than 6 months. In the case of a solitary brain metastasis, evidence of a disease-free interval of at least 3 months post-surgery. All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days.
2. Women who are pregnant, nursing, or planning to become pregnant during the course of the trial
3. Men who plan to father a child within 6 months of the last treatment
4. Use of any investigational drug within 30 days prior to screening
5. Significant cardiac disease including patients who have or who are at significant risk of developing prolongation of QTc
6. Severe and/or uncontrolled medical disease
7. Known chronic liver disease
8. Known human immunodeficiency virus (HIV) infection
9. Previous radiotherapy to 25% or more of the bone marrow
10. Radiation therapy in the 4 weeks prior to study entry
11. Prior exposure to a tyrosine kinase inhibitor

Date of first enrolment

15/12/2009

Date of final enrolment

04/08/2014

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

The Royal Marsden Hospital NHS Foundation Trust

London

United Kingdom

SW3 6JJ

Sponsor information

Organisation

The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research (ICR) (UK)

ROR

<https://ror.org/0008wzh48>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK) (ref: C28772/A11401)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Novartis (UK)

Alternative Name(s)

Novartis AG, Novartis International AG

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from nicam-icrctsu@icr.ac.uk.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		16/02/2024	05/03/2024	Yes	No
Basic results				No	No
HRA research summary			28/06/2023	No	No